Happy Friday all! Well, thankfully we were less stressed after last night’s presidential debate…a little saner!? As if the global Covid pandemic hadn’t already created enough stress for the general public by forcing them to adopt a more restricted lifestyle, they are now facing the high probability of other major changes related to executive administration and new mandates arriving with colder weather. While we are trapped in our homes, it is not surprising that many are experiencing acute tension and anxiety, exacerbated by the contentious election. People are under pressure and looking for coping mechanisms. That is why we found the top name in equity searches by your clients to be so intriguing.
Aptinyx Inc (APTX) was the equity to surge across general investors this past week. APTX is a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders. On Monday, the company announced positive results from the Phase 2 study of its novel NMDA receptor modulator in patients with post-traumatic stress disorder (PTSD). The study demonstrated statistically significant and clinically meaningful efficacy results and a favorable adverse event and tolerability profile. Shares of the company spiked from $3.70 to $8 on the news. The stock has given up those gains and reversed lower. Adding to the pressure was the announcement of a secondary offering.
TrackStarIQ Data
TOP STOCKS – BY Retail (Total Traffic) This Week
TOP STOCKS- BY RETAIL (Surge Traffic) This Week
TOP ETFs By RETAIL (Total Traffic) This Week
The volatile price action certainly caught our attention. APTX witnessed a surge of 63,150% in traffic from retail investors, the biggest jump we observed during the week. It is questionable that so many people would be researching a name that had such positive news just to try and short or sell shares.
Rather it more likely lines up to a possible buying opportunity given the pullback around the secondary. SVBLeerink has the stock rated as a “buy” and raised its price target to $14 from $12 on a Sum-of-the-Parts basis following the test results. Certainly, PTSD has a large Total Available Market as illustrated by the surge in interest in APTX. This is a name Financial Advisors should have on the radar to potentially ease stress around returns and will find appeal with your clients who are actively doing their own stress test on this stock.
| RANK | TOP STOCKS – BY Retail (Total Traffic) This Week | RANK | TOP STOCKS- BY RETAIL (Surge Traffic) This Week | RANK | TOP ETFs By RETAIL (Total Traffic) This Week |
|---|---|---|---|---|---|
| 1 | TSLA | 1 | APTX | 1 | SPY |
| 2 | AAPL | 2 | CBLI | 2 | QQQ |
| 3 | NIO | 3 | WEI | 3 | SLV |
| 4 | ES | 4 | IMUN | 4 | SQQQ |
| 5 | NFLX | 5 | ANCN | 5 | UVXY |
| 6 | SNAP | 6 | GTEC | 6 | ARKK |
| 7 | WKHS | 7 | UXIN | 7 | TAN |
| 8 | HTZ | 8 | DOGZ | 8 | GLD |
| 9 | SRNE | 9 | ASTC | 9 | XLK |
| 10 | AMZN | 10 | RESI | 10 | IWM |
| 11 | DKNG | 11 | XYF | 11 | VXX |
| 12 | T | 12 | BSTC | 12 | ARKW |
| 13 | ZM | 13 | MKD | 13 | XLE |
| 14 | WEI | 14 | CCNC | 14 | GDX |
| 15 | FB | 15 | JFU | 15 | TLT |
| 16 | V | 16 | BIMI | 16 | ARKG |
| 17 | KXIN | 17 | ACOR | 17 | CLOU |
| 18 | SPCE | 18 | LOGI | 18 | XLY |
| 19 | JKS | 19 | MTP | 19 | TECL |
| 20 | SPAQ | 20 | CIH | 20 | ICLN |